智通财经APP讯，山东新华制药股份(00719)发布2024年年度业绩，营业收入84.66亿元(人民币，下同)，同比增加4.51%;归母净利润4.7亿元，同比减少5.33%;基本每股收益0.69元;拟派发末期股息每股0.25元。
公告称，年内取得药品批件36个，其中制剂新产品批件22个、原料药新产品批件5个、一致性评价批件9个，取得国际注册文号20个，兽药生产批件23个，申请专利109件，获得授权专利57件，均创历史新高。
制剂新产品及动保制剂实现销售收入同比翻番。全年有22个制剂新产品投放市场。OAB-14 等重大创新药物研发加快推进。布洛芬原料药被列为第八批国家制造业单项冠军。公司入选国务院国资委“双百企业”名单。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.